Evidence map›Paper›PMID 37660689›Full record

ArticleJournal of vascular research2023

RhoA/ROCK Signaling Is Involved in Pathological Retinal Neovascularization.

Fen Tang, Kongqian Huang, Biyan Peng, Wen Deng, Ning Su, Fan Xu, Mingyuan Zhang, Haibin Zhong

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of vascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fen TangDepartment of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region and Guangxi Key Laboratory of Eye Health and Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology and Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.
Kongqian HuangDepartment of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region and Guangxi Key Laboratory of Eye Health and Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology and Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.
Biyan PengLaboratory Animal Center, Guangxi Medical University, Nanning, China.
Wen DengDepartment of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region and Guangxi Key Laboratory of Eye Health and Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology and Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.
Ning SuDepartment of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region and Guangxi Key Laboratory of Eye Health and Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology and Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.
Fan XuDepartment of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region and Guangxi Key Laboratory of Eye Health and Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology and Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.
Mingyuan ZhangLaboratory Animal Center, Guangxi Medical University, Nanning, China.
Haibin ZhongDepartment of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region and Guangxi Key Laboratory of Eye Health and Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology and Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the study was to evaluate the effect of the RhoA/ROCK inhibitor Fasudil on retinal neovascularization (NV) in vivo and angiogenesis in vitro.

methodsC57BL/6 was used to establish an OIR model. First, RhoA/ROCK expression was first examined and compared between OIR and healthy controls. Then, we evaluated the effect of Fasudil on pathological retinal NV. Whole-mount retinal staining was performed. The percentage of NV area, the number of neovascular tufts (NVT), and branch points (BP) were quantified. Finally, human umbilical vein endothelial cells (HUVECs) were used to investigate the effect of Fasudil on angiogenesis.

resultsReal-time PCR and Western blotting showed that ROCK expression in retinal tissue was statistically upregulated in OIR. Furthermore, we found that Fasudil attenuated the percentage of NV area, the number of NVT, and BP significantly. In addition, Fasudil could suppress the proliferation and migration of HUVECs induced by VEGF.

conclusionsRhoA/ROCK might be involved in the pathogenesis of OIR. And its inhibitor Fasudil could suppress retinal NV in vivo and angiogenesis in vitro. Fasudil may be a potential treatment strategy for retinal vascular diseases.

Indexed as

Retinal Neovascularization1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsDisease Models, AnimalHumansHuman Umbilical Vein Endothelial CellsMiceMice, Inbred C57BLNeovascularization, PathologicRetina1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinefasudilFasudilOxygen-induced retinopathyRetinal neovascularizationRhoA/ROCK

Identifiers

PMID37660689
PMCPMC10614457
OpenAlexW4386406951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.